The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity

Chemico-Biological Interactions

Volumn 174, Issue 3, 2008, Pages 141-146

  Seo, Kyung Ah ^a   Kim, Hyunmi ^a   Ku, Hei Young ^a   Ahn, Hee Jeong ^a   Park, Soo Jin ^a   Bae, Soo Kyung ^b   Shin, Jae Gook ^a,b   Liu, Kwang Hyeon ^a,c  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bupropion; Citral; CYP2B6; Geraniol; Inhibition; Monoterpenoids

Indexed keywords

5,5 DIMETHYL 1,3 CYCLOHEXANEDIONE; AMFEBUTAMONE; BORNEOL; CAMPHENE; CAMPHOR; CINEOLE; CINNAMYL ACETATE; CINNAMYL ALCOHOL; CITRAL; CITRONELLIC ACID; CYMENE; CYTOCHROME P450 2B6; DIHYDROCARVEOL; ENZYME INHIBITOR; GERANIC ACID; GERANIOL; ISOBORNEOL; ISOPULEGOL; LIMONENE; LINALOOL; MENTHOL; MYRCENE; PERILLALDEHYDE; TERPENE; TERPENOID DERIVATIVE; TERPINENE; TERPINEOL; THIOTEPA;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MONOTERPENES; OXIDOREDUCTASES, N-DEMETHYLATING; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES;

DRYOBALANOPS;

EID: 48649085065     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.06.003     Document Type: Article

References (35)

1. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., and Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
2. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., and Greenblatt D.J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28 (2000) 1176-1183
3. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306 (2003) 287-300
4. Bae S.K., Cao S., Seo K.A., Kim H., Kim M.J., Shon J.H., Liu K.H., Zhou H.H., and Shin J.G. Cytochrome P450 2B6 (CYP2B6) catalyzes the formation of pharmacologically active sibutramine metabolites in human liver microsomes. Drug Metab. Dispos. (2008)
5. Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Decosterd L., Blievernicht J., Saussele T., Gunthard H.F., Schwab M., Eichelbaum M., Telenti A., and Zanger U.M. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81 (2007) 557-566
6. Turpeinen M., Nieminen R., Juntunen T., Taavitsainen P., Raunio H., and Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab. Dispos. 32 (2004) 626-631
7. Richter T., Murdter T.E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M., and Zanger U.M. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308 (2004) 189-197
8. Wang C. Research advances on metabolism of effective constituents of traditional Chinese medicine. Hebei Yike Daxue Xuebao 25 (2004) 49-52
9. Abu-Lafi S., Odeh I., Dewik H., Qabajah M., Hanus L.O., and Dembitsky V.M. Thymol and carvacrol production from leaves of wild Palestinian Majorana syriaca. Bioresour. Technol. (2007)
10. Sell C.S., and Pybuss D.H. The Chemistry of Fragrances (1999), Springer Verlag
11. Kintziou H., Chinou E., and Chinou I. Antimicrobial activity of essential oils from Greek plants: applications and therapeutic uses. Epitheorese Klinikes Farmakologias kai Farmakokinetikes 15 (2001) 15-20
12. Tokuda K. Production of fragrant rayon. Frag. J. 32 (2004) 73-76
13. Wang G., Tang W., and Bidigare R.R. Terpenoids as therapeutic drugs and pharmaceutical agents. Nat. Prod. (2005) 197-227
14. Ravid U., and Putievsky E. Constituents of essential oils from Majorana syriaca, Coridothymus capitatus and Satureja thymbra*. Planta Med. 49 (1983) 248-249
15. Stroemgaard K. Medicinal chemistry of ginkgolides from Ginkgo biloba. Med. Chem. Bioact., Nat. Prod. (2006) 301-323
16. Broughan C., and Odours. emotions, and cognition-how odours may affect cognitive performance. Int. J. Aromather. 12 (1992) 92-98
17. Guitton J., Buronfosse T., Desage M., Flinois J.P., Perdrix J.P., Brazier J.L., and Beaune P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth. 80 (1998) 788-795
18. Chauret N., Gauthier A., and Nicoll-Griffith D.A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 26 (1998) 1-4
19. Kim M.J., Kim H., Cha I.J., Park J.S., Shon J.H., Liu K.H., and Shin J.G. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19 (2005) 2651-2658
20. Segel I.H. Enzyme kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1975), Wiley-Interscience, New York
21. Liu K.H., Lee Y.M., Shon J.H., Kim M.J., Lee S.S., Yoon Y.R., Cha I.J., and Shin J.G. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 34 (2004) 429-438
22. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., BEaune P., and de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9 (1999) 295-306
23. Mimura M., Baba T., Yamazaki H., Ohmori S., Inui Y., Gonzalez F.J., Guengerich F.P., and Shimada T. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21 (1993) 1048-1056
24. Nakamura K., Ariyoshi N., Iwatsubo T., Fukunaga Y., Higuchi S., Itoh K., Shimada N., Nagashima K., Yokoi T., Yamamoto K., Horiuchi R., and Kamataki T. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol. Pharm. Bull. 28 (2005) 882-885
25. Stresser D., and Kupfer D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab. Dispos. 27 (2004) 517-525
26. Huang Z.F., Massey J.B., and Via D.P. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem. Pharmacol. 59 (2000) 187-194
27. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., and Gillam E.M.J. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30 (2002) 869-874
28. Carnesecchi S., Schneider Y., Ceraline J., Duranton B., Gosse F., Seiler N., and Raul F. Geraniol, a component of plant essential oils, inhibits growth and polyamine biosynthesis in human colon cancer cells. J. Pharmacol. Exp. Ther. 298 (2001) 197-200
29. Kim H., Yoon Y.J., Shon J.H., Cha I.J., Shin J.G., and Liu K.H. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab. Dispos. 34 (2006) 521-523
30. Liu K.H., Kim M.J., Shon J.H., Moon Y.S., Seol S.Y., Kang W., Cha I.J., and Shin J.G. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 35 (2005) 27-38
31. Yoshida N., Takagi A., Kitazawa H., Kawakami J., and Adachi I. Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol. Appl. Pharmacol. 209 (2005) 167-173
32. Bryant B.P., and Mezine I. Alkylamides that produce tingling paresthesia activate tactile and thermal trigeminal neurons. Brain Res. 842 (1999) 452-460
33. Liston B.W., Nines R., Carlton P.S., Gupta A., Aziz R., Frankel W., and Stoner G.D. Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Cancer Res. 63 (2003) 2399-2403
34. Ong T.P., Heidor R., de Conti A., Dagli M.L., and Moreno F.S. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 27 (2006) 1194-1203
35. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., and Waxman D.J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25 (1997) 985-993